Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Great find upomega - hopefully we'll see an RNS for that news soon.
Global Fund approval for HIV diagnostic
Burnet Institute
20 November, 2019
Img 6929 510x288
In the lead-up to World AIDS Day, Burnet Institute is showcasing our latest successes and initiatives in the HIV field …
Today we can announce that a simple, low-cost, rapid HIV diagnostic developed by Burnet and commercialised by our partners at Omega Diagnostics, UK, has been endorsed by the Expert Review Panel for Diagnostics (ERPD), hosted by the Global Fund to Fight AIDS, Tuberculosis and Malaria.
This means that the test may be procured with Global Fund and/or UNITAID funds, which support major aid agencies operating in many of the poorest countries in the world.
While most countries now have policies that allow all HIV-infected patients to receive life-saving antiretroviral therapy regardless of their CD4 T-cell count, the VISITECT® CD4 Advanced Disease test can identify whether that person already has advanced HIV disease (a CD4 T-cell count below 200) when they are first diagnosed with HIV infection.
For these patients, who represent the majority of new HIV diagnoses in many resource-poor countries, a package of additional, urgent interventions are needed to address the risks of AIDS complications that often result in death before the antiretrovirals can stabilize the patient’s immune system.
These interventions are widely available, but their effective use relies on first determining the patient’s CD4 count.
Burnet Institute Deputy Director and Co-Head, Global Health Diagnostics Development, Associate Professor David Anderson, said the ERDP’s validation is hugely significant.
“It gives the green light for the aid agencies delivering HIV care to tens of millions of people in disadvantaged communities around the world to take advantage of this innovation,” Associate Professor Anderson said.
“The problem this addresses is that many patients are already suffering what we would have called full-blown AIDS when they are first diagnosed with HIV.
“This test allows us to see who’s already really sick and needs additional interventions and advanced care, versus those who are still relatively healthy and whose immune system hasn’t suffered too much.”
Associate Professor Anderson said the opportunity to make the VISITECT® CD4 Advanced Disease test available globally to the people who need it most represents the culmination of more than a decade’s research and development by Burnet and project partner, Omega Diagnostics.
“Our aim was to make something that could be used anywhere by a minimally trained healthcare worker, and it’s the only true point of care test for measuring CD4 T-cells, without the need for any instrumentation” he said.
“Clinical trials have shown that the visual result of this test can be read by eye to give the right result in the vast majority of cases, so that no matter where or when you’re diagnosed with HIV, no matter where your health care system is, you’re able to get the
Below article taken from The Burnets Website. Maybe a reminder as to the potential of cd4.
9 – Implementation of the VISITECT® CD4 and VISITECT® Advanced Disease point-of-care tests.
Burnet is supporting the manufacturing and rollout of the innovative CD4 tests developed at the Institute. Now licensed to Omega Diagnostics for manufacture and sale worldwide, the tests have achieved the CE Mark for products sold in Europe. They are being rolled out in key countries this year, allowing people at risk of HIV infection to test themselves regularly
jaykeyboy.
What are you referring to when you say eu seven bagger. ..
Here we go again.the clan at it again
Also.notice how stock is sold on any whiff of good news.what does that tell you about what is going on here. It tells me alot.this is deliberately being manipulated.
Dibs
try mirage.com news 25 ways to eliminate hiv. Cant provide link as doing this from my phone. Tou should be able to find it by googling under news
That’s interesting up, could you provide a link to the article please?
The following may be of interest which I posted on advfn
There is a small article written by Burnett institute posted on mirage website.basically saying that cd4 is be rolled out in Africa targeting self testing at home.if that's the case eventually we should see global sales.also I'm surprised Abbott labs have not shown interest in omega
Looks like the rally is over for now.At least the price has held considering someone dumped 50k shares
Possibly. Even though it was a small number of small trades nonetheless the best day here for a good while. Not saying a lot! Especially after a steady sell off in October. Maybe a new month - new trend? We can but hope and be interesting if this continues next week.
So have we got an update sometime next week?